Buruli Ulcer, Nigeria by Chukwuekezie, Okechukwu et al.
LETTERS
782  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 5, May 2007 782  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 5, May 2007
References
  1.   Migliori GB, Loddenkemper R, Blasi F, 
Raviglione MC. 125 years after Robert 
Koch’s discovery of the tubercle bacil-
lus: the new XDR-TB threat. Is “science” 
enough to tackle the epidemic? Eur Respir 
J. 2007;29:423–7.
  2.   Laszlo A, Rahman M, Espinal M, Ravi-
glione M; WHO/IUATLD Network of 
Supranational Reference Laboratories. 
Quality assurance programme for drug 
susceptibility testing of Mycobacterium 
tuberculosis in the WHO/IUATLD Supra-
national Laboratory Network: ﬁ  ve rounds 
of proﬁ  ciency testing 1994–1998. Int J Tu-
berc Lung Dis. 2002;6:748–56.
  3.   World  Health  Organization.  Extensively 
drug-resistant tuberculosis (XDR-TB): 
recommendations for prevention and 
control. Wkly Epidemiol Rec. 2006;81: 
430–2.
    4.    Shah NS, Wright A, Bai G-H, Barrera 
L, Boulahbal F, Martín-Casabona N, et 
al. Worldwide emergence of extensively 
drug-resistant tuberculosis. Emerg Infect 
Dis. 2007;13:380–7.
  5.   Ferrara G, Richeldi L, Bugiani M, Cirillo 
D, Besozzi G, Nutini S, et al. Management 
of multidrug-resistant tuberculosis in Italy. 
Int J Tuberc Lung Dis. 2005;9:507–13.
  6.   Gandhi NR, Moll A, Sturm AW, Pawinski 
R, Govender T, Lalloo U, et al. Extensive-
ly drug-resistant tuberculosis as a cause of 
death in patients co-infected with tuber-
culosis and HIV in a rural area of South 
Africa. Lancet. 2006;368:1575–80.
Address for correspondence: Giovanni Battista 
Migliori, WHO Collaborating Centre for TB and 
Lung Diseases, Fondazione S. Maugeri, Care 
and Research Institute/TBNET Secretariat/Stop 
TB Italy, via Roncaccio 16, 21049, Tradate, 
Italy; email: gbmigliori@fsm.it
Buruli Ulcer, 
Nigeria
To the Editor: Buruli ulcer (BU), 
a neglected tropical disease caused by 
Mycobacterium ulcerans, is character-
ized by necrosis of subcutaneous tis-
sue, leading to chronic, painless, and 
progressive ulcers. Without proper 
treatment, BU results in severe and 
permanent disability in more than a 
quarter of patients. Most patients are 
children <15 years of age. BU has 
been reported in >30 countries (1). The 
World Health Organization (WHO) 
has described the epidemiology, clini-
cal features, diagnosis, and treatment 
of BU (1–3).
In 1967, Gray et al. described 
4 BU cases in the Benue River Val-
ley in Nigeria (4). The authors also 
described unpublished reports of the 
disease in Banbur, Adamawa State, 
in the upper part of the Benue River 
Valley. In 1976, Oluwasanmi et al. 
described 24 BU cases in and around 
Ibadan (5). Since then, there has been 
no ofﬁ  cial report of BU in Nigeria. 
However, unofﬁ  cial reports indicate 
that the disease is still present in the 
country. For example, between 1998 
and 2000, BU cases from the Lep-
rosy and Tuberculosis Hospital in 
Moniaya-Ogoja, Cross River State, 
were bacteriologically conﬁ  rmed  at 
the Institute of Tropical Medicine in 
Belgium (6). More recently, patients 
from Nigeria have been treated in the 
neighboring countries of Benin (7) 
and Cameroon (8).
To clarify the BU situation in Ni-
geria, the government, with technical 
assistance from WHO, carried out a 
rapid assessment in the southern and 
southeastern states of the country, 
where cases had been previously re-
ported. Preassessment sensitization 
workshops for health workers within 
the selected states were held in June 
and July 2006. The assessment took 
place November 15–19, 2006. The 
team, which was made up of interna-
tional experts and national and state 
health ofﬁ   cials, was divided into 2 
groups. Group A visited Akwa Ibom 
and Cross Rivers States, and group B 
visited Anambra, Ebonyi, and Enugu 
States.
Based on the WHO case deﬁ  ni-
tions (1), 14 of 37 patient examined 
were considered likely to have BU (9 
active and 5 inactive cases); 9 were 
children <15 years of age. Eight pa-
tients were female, and 6 were male. 
One of the patients with active disease 
had the edematous form, 1 had osteo-
myelitis and ulcer, and the other 7 had 
ulcers (Figure). Ten of the patients 
had lesions on the lower limbs, 3 on 
the upper limbs, and 1 on the face. All 
cases were documented by registra-
tion on a modiﬁ  ed version of the BU 
02 form (1) and photography. Swab 
specimens were taken from all active 
ulcerative lesions. A ﬁ  ne-needle  as-
piration technique was used to obtain 
specimens from the edematous pa-
tient. In 4 (44%) of the 9 patients with 
active cases, the clinical diagnosis was 
conﬁ  rmed by the IS2404 PCR at the 
Institute of Tropical Medicine.
The locations and number of 
cases identiﬁ  ed in each are as follows: 
Iﬁ  te Ogwari village, Ayamelum Local 
Government Area (LGA), Anambra 
State (4 cases); Ndo Etok village, Ogo-
ja LGA, Cross River State (3 cases); 
Nkpo Hamida village, Igbo-Eze North 
LGA, Enugu State (1 case); Iburu vil-
lage, Ohaozora LGA, Ebonyi State 
(1 case); Akofu village, Ikwo LGA, 
Ebonyi State (1 case); Amagunze vil-
lage, Nkanu East LGA, Enugu State 
(1 case); Okro Mbokho village, East-
ern Obolo, Akwa Ibom State (1 case); 
Oron village, Oron LGA, Akwai Ibom 
State (1 case); and Ugwu Tank, Awka 
South LGA, Anambra State (1 case).
In conclusion, 30 years after the 
last publication (5) of cases in south-
western Nigeria, BU cases have been 
found in the southern and southeastern 
parts of the country. A similar phenom-
enon occurred in Cameroon, where 
a case search in 2001 in 2 districts 
where cases had last been reported 24 LETTERS
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years earlier found 436 active and in-
active cases (8). These ﬁ  ndings dem-
onstrate that BU has not disappeared 
from Nigeria and that the absence of 
any regular reporting should be inves-
tigated. Although the assessment team 
was able to visit only 5 of the 36 states 
(8 of 774 LGAs and 10 communities), 
it concluded that BU is still present in 
Nigeria and may be more prevalent 
than had been previously thought. The 
lack of familiarity with the disease by 
health workers may also have contrib-
uted to poor    reporting.
The assessment team recom-
mended 5 measures: 1) inclusion of 
BU treatment and control activities in 
the Tuberculosis and Leprosy Control 
Program at federal, state, and LGA 
levels to enhance surveillance of the 
disease; 2) training of health workers 
at all levels; 3) a detailed assessment 
of the extent of BU in the 5 states vis-
ited as well as in other states; 4) ap-
proaching partners supporting tuber-
culosis and leprosy control activities 
in Nigeria to include BU; and 5) in-
corporating BU into the national sur-
veillance system to allow better data 
collection.
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Figure. A typical Buruli ulcer in a 17-year-old boy identiﬁ  ed during the assessment.
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